Abstract: The present application relates to an antibody or an antigen-binding fragment thereof binding to ?-CTx. The antibody or an antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region and the light chain variable region comprise HCDR and LCDR sequences of the present application. The present application also relates to a corresponding isolated nucleic acid molecule, expression vector and host cell. In addition, the application also relates to a kit and a method for diagnosing osteoporosis in a subject.

Abstract: The present disclosure relates to the field of biomedical technology, and specifically to an antibody against human immunodeficiency virus type 1 p24 and type 2 p26 and uses thereof. The present disclosure provides an antibody or antigen-binding fragment thereof capable of specifically binding to human immunodeficiency virus type 1 p24 protein and human immunodeficiency virus type 2 p26 protein. The present disclosure also provides an antibody pair, kit and related uses thereof. Utilizing the antibody pair in immunoassays enables the simultaneous detection of HIV-1 p24 and HIV-2 p26 antigens, with the advantage of a lower limit of detection (LOD).

Abstract: The present disclosure provides an antibody specifically targeting cardiac troponin I. The present disclosure further provides antibody pairs and kits comprising the antibodies. The present disclosure further provides the use of these antibodies to detect levels of cardiac troponin I, and to diagnose myocardial injury.

Abstract: The present disclosure provides an antibody specifically targeting cardiac troponin I. The present disclosure further provides antibody pairs and kits comprising the antibodies. The present disclosure further provides uses of these antibodies to detect levels of cardiac troponin I, and to diagnose myocardial injury.

Abstract: The present application relates to a PINP-specific antibody, kit and use thereof. Specifically, the present invention provides a PINP-specific antibody, as well as a kit containing the antibody, and use thereof in detecting the presence or level of tPINP in a sample.

Abstract: The present disclosure provides an antibody specifically targeting cardiac troponin I. The present disclosure further provides antibody pairs and kits comprising the antibodies. The present disclosure further provides the use of these antibodies to detect levels of cardiac troponin I, and to diagnose myocardial injury.

Abstract: The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Abstract: Disclosed is a method for detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments. The method uses antibodies or antigen binding fragments that specifically recognize epitopes on IGFBP-4 fragments. The IGFBP-4 fragments include the N-terminal and C-terminal fragments resulting from PAPP-A dependent cleavage of IGFBP-4. Assay and diagnostic methods using detection of IGFBP-4 fragments are also disclosed.

Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.

Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.

Abstract: The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.

Abstract: The present invention provides antibodies against glycosylated proBNP and NT-proBNP. The antibodies are suitable for precise immunodetection of both of the proteins in human blood. The glycosylated forms of proBNP and NT-proBNP may be utilized as an antigen for antibody generation as well as a calibrator or immunological standard in different types of immunoassays. The invention thus also relates to a stable standard or calibrator pro-Brain Natriuretic Peptide (proBNP) preparation for use in a method for detecting BNP immunoreactivity in a sample, the preparation comprising glycosylated proBNP or a fragment thereof. In addition, the present invention is directed to an assay for precisely detecting the NT-proBNP circulating in a patient's blood, wherein the level of glycosylation of the proBNP molecule is exploited. Therapeutic applications are also contemplated.